BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD
3 November 2020

BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD

BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the...

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse